DOI:
10.1055/s-00000059
Pneumologie
LinksClose Window
References
Wong KK, Fracasso PM, Bukowski RM et al.
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Clin Cancer Res 2009;
15: 2552-2558
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.